COVID-19 Vaccine Effectiveness Among Older Adults - Summary - MDSpire

COVID-19 Vaccine Effectiveness Among Older Adults

  • By

  • Charlotte Laniece Delaunay

  • Alberto Mateo-Urdiales

  • Gloria Pérez-Gimeno

  • Karen O’Reilly

  • Marina Uras

  • Annika Erdwiens

  • Ivan Mlinarić

  • Gergő Túri

  • Iván Martínez-Baz

  • Adam Meijer

  • Ana Paula Rodrigues

  • Mihaela Lazăr

  • Neus Latorre-Margalef

  • Héloïse Lucaccioni

  • Nuno Verdasca

  • Antonino Bella

  • Maria Angeles Rafael de la Cruz Lopez

  • Eva Kelly

  • Vincent Enouf

  • Kristin Tolksdorf

  • Simona Puzelli

  • Ana Carmen Ibáñez Pérez

  • Margaret Fitzgerald

  • Shirley Masse

  • Djin-Ye Oh

  • Marlena Kaczmarek

  • Sabrina Bacci

  • Esther Kissling

  • VEBIS Primary Care Vaccine Effectiveness Group

  • Sanja Kurečić Filipović

  • Vesna Višekruna Vučina 

  • Ivana Ferenčak

  • Bernard Kaić

  • Katica Čusek Adamić

  • Mirjana Lana Kosanović Ličina

  • Ivana Mihin Huskić

  • Diana Nonković

  • Morana Tomljenović

  • Caroline Guerrisi

  • Cécile Souty

  • Thierry Blanchon

  • Titouan Launay

  • Alessandra Falchi

  • Marie Chazelle

  • Leïla Renard

  • Marie-Anne Rameix-Welti

  • Danielle Perez-Bercoff

  • Antonin Bal

  • Bruno Lina

  • Ralf Dürrwald

  • Barbara Biere

  • Janine Reiche

  • Marianne Wedde

  • Ute Preuß

  • Irmgard Stroetmann

  • Beatrix Oroszi

  • Viktória Velkey

  • Katalin Krisztalovics

  • Katalin Kristóf

  • Michael Joyce

  • Sara  Piacentini

  • Emanuela Giombini

  • Marzia Facchini

  • Angela Di Martino

  • Massimo Fabiani

  • Benedetta Bellini

  • Patrizio Pezzotti

  • Paola Stefanelli

  • Dirk Eggink

  • Anne Huiberts

  • Rianne van Gageldonk-Lafeber

  • Mariëtte Hooiveld

  • Ausenda Machado

  • Raquel Guiomar

  • João Almeida Santos

  • Licínia Gomes

  • Maria Elena Mihai

  • Alina Ivanciuc

  • Catalina Pascu

  • Sorin Dinu

  • Mihaela Oprea

  • Olivia Timnea

  • Adrian Jidovu

  • Susana Monge

  • Marcos Lozano

  • Francisco Pozo

  • Inmaculada Casas

  • Sonia Vázquez-Morón

  • Carmen Roman-Ortiz

  • Ignacio Campo-Palacio

  • Camino Trobajo-Sanmartín

  • Aitziber Echeverría

  • Itziar Casado

  • Guillermo Ezpeleta

  • Jesús Castilla

  • Ana Navascués

  • María Eugenia Portillo

  • June 15, 2026

  • 0 min

Share

Objective:

To estimate the effectiveness of COVID-19 vaccines administered during seasonal vaccination campaigns in Europe from September 29, 2025, to January 10, 2026, against medically attended, symptomatic SARS-CoV-2 infection among older adults.

Approach:
    Key Findings:
    • Overall COVID-19 vaccine effectiveness (VE) was 59% (95% CI, 14% to 83%) among older adults during the vaccination campaigns.
    • VE was 64% (95% CI, 8% to 89%) at 14 to 41 days and 52% (95% CI, −39% to 89%) at 42 to 83 days postvaccination.
    • The study included a low number of vaccinated cases (7 out of 125) compared to controls (374 out of 1921).
    Interpretation:

    Vaccines administered in autumn and winter 2025 to 2026 showed approximately 55% effectiveness against symptomatic disease among older adults within 2 months of vaccination.

    Limitations:
    • Limited sample size due to reduced SARS-CoV-2 circulation following vaccination campaigns.
    • Low vaccine uptake among vulnerable groups suggests missed opportunities for preventing symptomatic COVID-19, highlighting the need for targeted vaccination strategies.
    Conclusion:

    The findings indicate substantial short-term effectiveness of COVID-19 vaccines in older adults, but caution is needed in interpreting results due to sample size limitations.

Original Source(s)

COVID-19 Vaccine Effectiveness Among Older Adults

  • by Charlotte Laniece Delaunay, Alberto Mateo-Urdiales, Gloria Pérez-Gimeno, Karen O’Reilly, Marina Uras, Annika Erdwiens, Ivan Mlinarić, Gergő Túri, Iván Martínez-Baz, Adam Meijer, Ana Paula Rodrigues, Mihaela Lazăr, Neus Latorre-Margalef, Héloïse Lucaccioni, Nuno Verdasca, Antonino Bella, Maria Angeles Rafael de la Cruz Lopez, Eva Kelly, Vincent Enouf, Kristin Tolksdorf, Simona Puzelli, Ana Carmen Ibáñez Pérez, Margaret Fitzgerald, Shirley Masse, Djin-Ye Oh, Marlena Kaczmarek, Sabrina Bacci, Esther Kissling, VEBIS Primary Care Vaccine Effectiveness Group, Sanja Kurečić Filipović, Vesna Višekruna Vučina , Ivana Ferenčak, Bernard Kaić, Katica Čusek Adamić, Mirjana Lana Kosanović Ličina, Ivana Mihin Huskić, Diana Nonković, Morana Tomljenović, Caroline Guerrisi, Cécile Souty, Thierry Blanchon, Titouan Launay, Alessandra Falchi, Marie Chazelle, Leïla Renard, Marie-Anne Rameix-Welti, Danielle Perez-Bercoff, Antonin Bal, Bruno Lina, Ralf Dürrwald, Barbara Biere, Janine Reiche, Marianne Wedde, Ute Preuß, Irmgard Stroetmann, Beatrix Oroszi, Viktória Velkey, Katalin Krisztalovics, Katalin Kristóf, Michael Joyce, Sara  Piacentini, Emanuela Giombini, Marzia Facchini, Angela Di Martino, Massimo Fabiani, Benedetta Bellini, Patrizio Pezzotti, Paola Stefanelli, Dirk Eggink, Anne Huiberts, Rianne van Gageldonk-Lafeber, Mariëtte Hooiveld, Ausenda Machado, Raquel Guiomar, João Almeida Santos, Licínia Gomes, Maria Elena Mihai, Alina Ivanciuc, Catalina Pascu, Sorin Dinu, Mihaela Oprea, Olivia Timnea, Adrian Jidovu, Susana Monge, Marcos Lozano, Francisco Pozo, Inmaculada Casas, Sonia Vázquez-Morón, Carmen Roman-Ortiz, Ignacio Campo-Palacio, Camino Trobajo-Sanmartín, Aitziber Echeverría, Itziar Casado, Guillermo Ezpeleta, Jesús Castilla, Ana Navascués, María Eugenia Portillo

  • June 15, 2026

Related Content

Modeling the disruptive impact of the COVID-19 pandemic on nurses’ supply and wages

Predictive biomarkers of COVID-19 impact in renal transplant patients: an exploratory proteomic and cytokine analysis

Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primates